drugset / Trial / NCT00223938

Study of the Efficacy and Safety of Ferrlecit in the Maintenance Dosing in Hemodialysis Patients.

NCT00223938

Phase 4 Terminated 112 enrolled Sanofi
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a phase 4 clinical investigation of the efficacy and safety of Ferrlecit in the maintenance of iron stores and serum hemoglobin concentration in hemodialysis patients receiving Erythropoietin.

Timeline

Start
2003-12-30
Primary completion
2007-04-27
Completion
2007-04-27

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ferrous Sulfate Diagnostic / imaging agent Oral
Subject Sodium Ferric Gluconate Complex Unknown Intravenous

Indications